USP22-mediated Deubiquitination of PTEN Inhibits Pancreatic Cancer Progression by Inducing P21 Expression

Overview

Journal Mol Oncol

Specialties Molecular Biology
Oncology

Date 2021 Nov 7

PMID 34743406

Citations 10

Authors

Dianyun Ren

Yan Sun

Dan Li

Heshui Wu

Xin Jin

Affiliations

Soon will be listed here.

Abstract

Phosphatase and tensin homolog deleted on chromosome ten (PTEN) is a dual lipid and protein phosphatase. Multiple mechanisms contributing to the regulation of PTEN levels have been identified thus far, including post-translational modifications, epigenetic mechanisms, and transcriptional mechanisms. In the present study, we identified ubiquitin-specific peptidase 22 (USP22) as a novel deubiquitination-modifying enzyme of PTEN. Furthermore, by inducing deubiquitination and inhibiting the degradation of PTEN, USP22 could induce cyclin-dependent kinase inhibitor 1A (CDKN1A, also symboled as p21) expression in pancreatic cancer. Besides, MDM2 proto-oncogene (MDM2) inhibitor enhanced the antipancreatic cancer effects of USP22 overexpression. In addition to its regulation of MDM2-tumor protein p53 (p53) signaling, we found that PTEN could induce p21 expression by interacting with ankyrin repeat and KH domain containing 1 (ANKHD1) and inhibiting ANKHD1 binding to the p21 promoter. Taken together, our results indicate that ANKHD1 and MDM2 might be novel therapeutic targets in pancreatic cancer.

Citing Articles

A positive feedback loop of SRSF9/USP22/ZEB1 promotes the progression of ovarian cancer.

Wang J, Hu M, Min J, Li X Cancer Biol Ther. 2024; 25(1):2427415.

PMID: 39530604 PMC: 11559372. DOI: 10.1080/15384047.2024.2427415.

YTHDF1 gene inhibits epilepsy progression by epigenetic activation of PTEN gene.

Li M, Yang J, Gao L Heliyon. 2024; 10(20):e39481.

PMID: 39497959 PMC: 11533598. DOI: 10.1016/j.heliyon.2024.e39481.

USP22 as a key regulator of glycolysis pathway in osteosarcoma: insights from bioinformatics and experimental approaches.

Zhang Q, Zhu J, Xie J, Gu Y, Chen L PeerJ. 2024; 12:e17397.

PMID: 38784391 PMC: 11114114. DOI: 10.7717/peerj.17397.

Emerging roles of deubiquitinating enzymes in actin cytoskeleton and tumor metastasis.

Xue Y, Xue C, Song W Cell Oncol (Dordr). 2024; 47(4):1071-1089.

PMID: 38324230 DOI: 10.1007/s13402-024-00923-z.

Ubiquitin signaling in pancreatic ductal adenocarcinoma.

Lv S, Zhang J, Peng X, Liu H, Liu Y, Wei F Front Mol Biosci. 2024; 10:1304639.

PMID: 38174069 PMC: 10761520. DOI: 10.3389/fmolb.2023.1304639.

References

Zhang Q, Li X, Li Y, Chen S, Shen X, Dong X . Expression of the PTEN/FOXO3a/PLZF signalling pathway in pancreatic cancer and its significance in tumourigenesis and progression. Invest New Drugs. 2019; 38(2):321-328. DOI: 10.1007/s10637-019-00791-7. View

Xia L, Song M, Sun M, Chen W, Yang C . miR-486 Promotes Capan-2 Pancreatic Cancer Cell Proliferation by Targeting Phosphatase and Tensin Homolog Deleted on Chromosome 10 (PTEN). Front Genet. 2019; 10:541. PMC: 6588128. DOI: 10.3389/fgene.2019.00541. View

Daniel-Garcia L, Vergara P, Navarrete A, Gonzalez R, Segovia J . Simultaneous Treatment with Soluble Forms of GAS1 and PTEN Reduces Invasiveness and Induces Death of Pancreatic Cancer Cells. Onco Targets Ther. 2020; 13:11769-11779. PMC: 7680188. DOI: 10.2147/OTT.S260671. View

Huang X, Zhang Q, Lou Y, Wang J, Zhao X, Wang L . USP22 Deubiquitinates CD274 to Suppress Anticancer Immunity. Cancer Immunol Res. 2019; 7(10):1580-1590. DOI: 10.1158/2326-6066.CIR-18-0910. View

Wang X, Li X, Wei X, Jiang H, Lan C, Yang S . PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC. Signal Transduct Target Ther. 2020; 5(1):38. PMC: 7162990. DOI: 10.1038/s41392-020-0144-8. View

Leslie N, Yang X, Downes C, Weijer C . PtdIns(3,4,5)P(3)-dependent and -independent roles for PTEN in the control of cell migration. Curr Biol. 2007; 17(2):115-25. PMC: 1885949. DOI: 10.1016/j.cub.2006.12.026. View

de Almeida B, Machado-Neto J . Emerging functions for ANKHD1 in cancer-related signaling pathways and cellular processes. BMB Rep. 2020; 53(8):413-418. PMC: 7473474. View

Machado-Neto J, Campos P, Favaro P, Lazarini M, Lorand-Metze I, Costa F . Stathmin 1 is involved in the highly proliferative phenotype of high-risk myelodysplastic syndromes and acute leukemia cells. Leuk Res. 2013; 38(2):251-7. DOI: 10.1016/j.leukres.2013.11.013. View

Blind R . Disentangling biological signaling networks by dynamic coupling of signaling lipids to modifying enzymes. Adv Biol Regul. 2013; 54:25-38. PMC: 3946453. DOI: 10.1016/j.jbior.2013.09.015. View

10.

Hlobilkova A, Guldberg P, Thullberg M, Zeuthen J, Lukas J, Bartek J . Cell cycle arrest by the PTEN tumor suppressor is target cell specific and may require protein phosphatase activity. Exp Cell Res. 2000; 256(2):571-7. DOI: 10.1006/excr.2000.4867. View

11.

Wang X, Luo G, Zhang K, Cao J, Huang C, Jiang T . Hypoxic Tumor-Derived Exosomal miR-301a Mediates M2 Macrophage Polarization via PTEN/PI3Kγ to Promote Pancreatic Cancer Metastasis. Cancer Res. 2018; 78(16):4586-4598. DOI: 10.1158/0008-5472.CAN-17-3841. View

12.

Verma A, Guha S, Wang H, Fok J, Koul D, Abbruzzese J . Tissue transglutaminase regulates focal adhesion kinase/AKT activation by modulating PTEN expression in pancreatic cancer cells. Clin Cancer Res. 2008; 14(7):1997-2005. DOI: 10.1158/1078-0432.CCR-07-1533. View

13.

Tovar C, Rosinski J, Filipovic Z, Higgins B, Kolinsky K, Hilton H . Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci U S A. 2006; 103(6):1888-93. PMC: 1413632. DOI: 10.1073/pnas.0507493103. View

14.

Machado-Neto J, Lazarini M, Favaro P, Campos P, Scopim-Ribeiro R, Franchi Junior G . ANKHD1 silencing inhibits Stathmin 1 activity, cell proliferation and migration of leukemia cells. Biochim Biophys Acta. 2014; 1853(3):583-93. DOI: 10.1016/j.bbamcr.2014.12.012. View

15.

Li A, Qiu M, Zhou H, Wang T, Guo W . PTEN, Insulin Resistance and Cancer. Curr Pharm Des. 2017; 23(25):3667-3676. DOI: 10.2174/1381612823666170704124611. View

16.

Georgakilas A, Martin O, Bonner W . p21: A Two-Faced Genome Guardian. Trends Mol Med. 2017; 23(4):310-319. DOI: 10.1016/j.molmed.2017.02.001. View

17.

Kosinsky R, Zerche M, Saul D, Wang X, Wohn L, Wegwitz F . USP22 exerts tumor-suppressive functions in colorectal cancer by decreasing mTOR activity. Cell Death Differ. 2019; 27(4):1328-1340. PMC: 7205880. DOI: 10.1038/s41418-019-0420-8. View

18.

Liu H, Liu N, Zhao Y, Zhu X, Wang C, Liu Q . Oncogenic USP22 supports gastric cancer growth and metastasis by activating c-Myc/NAMPT/SIRT1-dependent FOXO1 and YAP signaling. Aging (Albany NY). 2019; 11(21):9643-9660. PMC: 6874452. DOI: 10.18632/aging.102410. View

19.

Chao J, Hollman R, Meyers W, Meili F, Matreyek K, Dean P . A Premalignant Cell-Based Model for Functionalization and Classification of Variants. Cancer Res. 2020; 80(13):2775-2789. DOI: 10.1158/0008-5472.CAN-19-3278. View

20.

Berger A, Knudson A, Pandolfi P . A continuum model for tumour suppression. Nature. 2011; 476(7359):163-9. PMC: 3206311. DOI: 10.1038/nature10275. View